Syros Pharmaceuticals, Inc. 4
4 · Syros Pharmaceuticals, Inc. · Filed Jul 6, 2016
Insider Transaction Report
Form 4
AISLING CAPITAL III LP
10% Owner
Transactions
- Purchase
Common Stock
2016-07-06$12.50/sh+400,000$5,000,000→ 908,565 total - Conversion
Common Stock
2016-07-06+508,565→ 508,565 total - Conversion
Series B Preferred Stock
2016-07-06−1,907,122→ 0 total→ Common Stock (508,565 underlying)
Footnotes (2)
- [F1]The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The securities are directly held by Aisling Capital III, LP ("Aisling"), and indirectly held by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms.